| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
AJDOVŠCINA, Slovenia—BIA Separations, a leading biochromatography development and manufacturing company, announced recently the expansion of its services with the opening of a new upstream processing (USP) laboratory.
 
The investment in the new facility comes in response to customer demand for services that optimize the critical interface between upstream and downstream processing for the robust and scalable production of complex molecules and biologics, such as viral vectors, phages and exosomes. The new USP facility will reportedly ensure biopharmaceutical manufacturing processing is developed and delivered to customers in an integrated way, with full coordination of critical steps, such as upstream choice of cell line; source and supply of materials; bioreactor processing parameters and the consequential impact on downstream product purification; formulation; and stability profiles.
 
“This month, BIA Separations celebrates our 20th Anniversary and we are delighted to mark it with the opening of this new USP facility,” Aleš Štrancar, CEO of BIA Separations, said in September as part of the announcement. “Alongside our many years’ experience and expertise in understanding and controlling bioprocesses, we now have the capability to manage the interface between upstream and downstream processes, which is key for complex biologics production.”
 
BIA Separations is a developer and manufacturer of Convective Interaction Media monolithic chromatographic columns for production, purification and analytics of large biomolecules; in addition, the company aims to provide unique in-process control tools to better understand and control the bioprocesses.
 

Related Topics

Published In

Volume 14 - Issue 10 | October 2018

October 2018

October 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue